Prime Medicine, Inc. Common Stock (PRME) — Strategic Asset Allocation Index
Prime Medicine, Inc. Common Stock (PRME) has a Strategic Asset Allocation Index of 8.6% as of June 2023. Strategic assets (PP&E of $20.56 Million plus long-term investments of $-) total $20.56 Million, measured against net assets of $240.10 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check how resilient are Prime Medicine, Inc. Common Stock's assets to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Prime Medicine, Inc. Common Stock Strategic Asset Allocation Index (2020–2022)
This chart shows how Prime Medicine, Inc. Common Stock's Strategic Asset Allocation Index has evolved across 3 annual periods from 2020 to 2022. As of June 2023, the index stands at 8.6%, representing strategic assets of $20.56 Million against net assets of $240.10 Million USD. See PRME FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Prime Medicine, Inc. Common Stock (2020–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Prime Medicine, Inc. Common Stock from 2020 to 2022, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see PRME market cap overview.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 6.0% | $19.01 Million | $19.01 Million | $- | $316.27 Million | ▼ -0.5 pp |
| 2021 | 6.5% | $15.68 Million | $15.68 Million | $- | $239.56 Million | ▲ +4.8 pp |
| 2020 | 1.8% | $596.00K | $596.00K | $- | $33.47 Million | — |